Integrating Depression Screening into HIV-care in Southern India.

将抑郁症筛查纳入印度南部的艾滋病毒护理。

基本信息

  • 批准号:
    7944025
  • 负责人:
  • 金额:
    $ 15.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2013-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): UNAIDS estimates that over 33 million people are currently living with the human immunodeficiency virus (HIV); 2.5 million of these persons live in India and Southern India has among the highest HIV rates in the country. HIV-positive individuals suffer a host of co-morbidities that impact quality of life and disease progression, not the least of which is depression. Limited data are available on depression among HIV-positive persons in India, although small studies suggest the prevalence ranges from 20-47%, indicating it is likely to affect a large number of people. In addition to the psychosocial suffering that accompanies depressive mood disorders, depression has been associated with reduced adherence to antiretroviral therapy and increased sexual risk taking in some cases, although the evidence for the latter is mixed. Depression is also associated with poor biologic outcomes, including lower CD4 counts, higher viral load, more rapid disease progression and shortened survival. Screening for and treating depression therefore should be an integral part of HIV care services. Effective medications and psychotherapies for treating depression are available in urban centers in India where HIV care is delivered, but there is currently no system to screen and refer depressed HIV-positive individuals to trained mental health personnel. Therefore, we propose a series of studies designed to determine the feasibility of integrating a screening and referral system for depression into HIV care settings, with the following specific aims: (1) Compare 3 depression scales to psychiatric diagnoses of depression to identify the most appropriate tool to screen HIV-positive individuals in South India for depression; (2) Estimate the prevalence and correlates of depression among HIV- patients seeking care in an urban HIV clinic to identify modifiable factors; and (3) Identify barriers and facilitators to integrating depression screening into existing HIV-care services through focus groups and in-depth interviews. PUBLIC HEALTH RELEVANCE: Depression can result in significant psychosocial suffering and has been associated with numerous adverse outcomes among HIV-positive persons, including reduced adherence and poor biologic outcomes. Screening for and treating depression would contribute to primary HIV prevention by reducing viral load and thus transmission, and secondary prevention by reducing the psychosocial suffering and increasing quality of life among HIV-positive individuals in India.
描述(由申请人提供):联合国艾滋病规划署估计,目前有3300多万人感染人类免疫缺陷病毒(艾滋病毒);其中250万人生活在印度,印度南部是该国艾滋病毒感染率最高的地区之一。艾滋病毒阳性个体患有一系列影响生活质量和疾病进展的合并症,其中最重要的是抑郁症。关于印度艾滋病毒阳性者抑郁症的数据有限,尽管小型研究表明患病率在20- 47%之间,这表明它可能影响到大量人群。除了伴随抑郁性情绪障碍的心理社会痛苦之外,抑郁症还与抗逆转录病毒治疗依从性降低和在某些情况下性风险增加有关,尽管后者的证据好坏参半。抑郁症还与不良的生物学结局相关,包括较低的CD 4计数,较高的病毒载量,更快的疾病进展和缩短的生存期。因此,筛查和治疗抑郁症应该是艾滋病毒护理服务的一个组成部分。在印度提供艾滋病毒护理的城市中心,可以获得治疗抑郁症的有效药物和心理疗法,但目前没有系统来筛选抑郁的艾滋病毒阳性者并将其转介给训练有素的心理健康人员。因此,我们提出了一系列的研究,旨在确定整合抑郁症的筛查和转诊系统到艾滋病毒护理环境的可行性,具有以下具体目标:(1)比较3抑郁症量表的抑郁症的精神诊断,以确定最合适的工具来筛选艾滋病毒阳性的个人在印度南部的抑郁症;(2)估计抑郁症的患病率和相关因素在城市艾滋病诊所寻求治疗的艾滋病患者,以确定可改变的因素;(3)通过焦点小组和深入访谈,确定障碍和促进因素,将抑郁症筛查纳入现有的艾滋病护理服务。 公共卫生相关性:抑郁症可导致严重的心理社会痛苦,并与艾滋病毒阳性者中的许多不良后果有关,包括依从性降低和生物学结局不良。筛查和治疗抑郁症将有助于通过减少病毒载量从而减少传播来进行艾滋病毒初级预防,并通过减少印度艾滋病毒阳性者的心理痛苦和提高生活质量来进行二级预防。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lisa E Manhart其他文献

Lisa E Manhart的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lisa E Manhart', 18)}}的其他基金

Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance
美国沙眼衣原体和生殖支原体的累积负担:对筛查指南和抗菌素耐药性的影响
  • 批准号:
    10397644
  • 财政年份:
    2021
  • 资助金额:
    $ 15.95万
  • 项目类别:
Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance
美国沙眼衣原体和生殖支原体的累积负担:对筛查指南和抗菌素耐药性的影响
  • 批准号:
    10616677
  • 财政年份:
    2021
  • 资助金额:
    $ 15.95万
  • 项目类别:
Ureaplasmas in acute and persistent urethritis: clinical implications
解脲支原体在急性和持续性尿道炎中的临床意义
  • 批准号:
    8068051
  • 财政年份:
    2010
  • 资助金额:
    $ 15.95万
  • 项目类别:
Mycoplasma genitalium Susceptibility and Treatment
生殖支原体的易感性和治疗
  • 批准号:
    7962199
  • 财政年份:
    2009
  • 资助金额:
    $ 15.95万
  • 项目类别:
Ureaplasmas in acute and persistent urethritis: clinical implications
解脲支原体在急性和持续性尿道炎中的临床意义
  • 批准号:
    7573466
  • 财政年份:
    2007
  • 资助金额:
    $ 15.95万
  • 项目类别:
Ureaplasmas in acute and persistent urethritis: clinical implications
解脲支原体在急性和持续性尿道炎中的临床意义
  • 批准号:
    7268263
  • 财政年份:
    2007
  • 资助金额:
    $ 15.95万
  • 项目类别:
Ureaplasmas in acute and persistent urethritis: clinical implications
解脲支原体在急性和持续性尿道炎中的临床意义
  • 批准号:
    7365146
  • 财政年份:
    2007
  • 资助金额:
    $ 15.95万
  • 项目类别:
Principles of STD and HIV Research
性病和艾滋病毒研究原理
  • 批准号:
    7076945
  • 财政年份:
    2004
  • 资助金额:
    $ 15.95万
  • 项目类别:
Principles of STD and HIV Research
性病和艾滋病毒研究原理
  • 批准号:
    7470557
  • 财政年份:
    2004
  • 资助金额:
    $ 15.95万
  • 项目类别:
Principles of STD and HIV Research
性病和艾滋病毒研究原理
  • 批准号:
    7262564
  • 财政年份:
    2004
  • 资助金额:
    $ 15.95万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 15.95万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 15.95万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 15.95万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 15.95万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 15.95万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 15.95万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 15.95万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 15.95万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 15.95万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 15.95万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了